Publication:
CpG DNA, liposome and refined antigen oral cholera vaccine

dc.contributor.authorRatree Leelawongtawonen_US
dc.contributor.authorSrinuan Somroopen_US
dc.contributor.authorUrai Chaisrien_US
dc.contributor.authorPongsri Tongtaween_US
dc.contributor.authorManas Chongsa-nguanen_US
dc.contributor.authorThareerat Kalambahetien_US
dc.contributor.authorPramuan Tapchaisrien_US
dc.contributor.authorSathit Pichyangkulen_US
dc.contributor.authorYuwaporn Sakolvareeen_US
dc.contributor.authorHisao Kurazonoen_US
dc.contributor.authorHideo Hayashien_US
dc.contributor.authorWanpen Chaicumpaen_US
dc.contributor.otherMahidol Universityen_US
dc.contributor.otherThammasat Universityen_US
dc.contributor.otherArmed Forces Research Institute of Medical Sciences, Thailanden_US
dc.contributor.otherOkayama Universityen_US
dc.contributor.otherUniversity of Tsukubaen_US
dc.date.accessioned2018-07-24T03:24:10Z
dc.date.available2018-07-24T03:24:10Z
dc.date.issued2003-12-01en_US
dc.description.abstractAn oral cholera vaccine made up of three Vibrio cholerae antigens, i.e. lipopolysaccharide (LPS), recombinant toxin co-regulated pili (rTcpA) and heat-treated cholera toxin (H-CT) has been developed in six different formulations. Eight-week-old Wistar rats were divided into nine groups and immunized as follows: the first group received the oral vaccine 1 consisting of the three antigens (LPS, rTcpA and H-CT) associated with a liposome (L) and bacterial CpG-DNA (ODN#1826). The rats of groups 2 and 3 received oral vaccines 2 and 3 consisting of the liposome-associated three antigens with and without non-bacterial CpG-DNA (ODN#1982), respectively. Rats of groups 4 received oral vaccine 4 consisting of the three antigens mixed with the ODN#1826, similar to vaccine 1, but without liposome. Rats of groups 5 and 6 received oral vaccines 5 and 6 consisting of the three antigens with and without ODN#1982, respectively, similar to vaccines 2 and 3, but without liposome. Rats of groups 7, 8 and 9 received oral placebos, namely liposomes (L), ODN#1826 (CpG), and vaccine diluent, i.e. 5% NaHCO3solution, respectively. All vaccines were given in three doses at 14-day intervals. It was found that the combination of liposome and ODN#1826 in vaccine 1 evoked the highest immune response to V. cholerae antigen compared to other vaccine formulations and placebos, as measured by the appearance of antigen-specific antibody-producing cells in the intestinal lamina propria. The immunogenicity according to the magnitude of the immune response was: V1>V2=V3>V4>V5=V6>V7=V8=V9. The results of this study indicate that CpG-DNA and liposome are effective mucosal adjuvants for an oral cholera vaccine prepared from refined V. cholerae antigens and their combination seems to be synergistic. The potential role of liposome as a vaccine delivery vehicle has been confirmed.en_US
dc.identifier.citationAsian Pacific Journal of Allergy and Immunology. Vol.21, No.4 (2003), 231-239en_US
dc.identifier.issn0125877Xen_US
dc.identifier.other2-s2.0-2942564274en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/20868
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=2942564274&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectMedicineen_US
dc.titleCpG DNA, liposome and refined antigen oral cholera vaccineen_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=2942564274&origin=inwarden_US

Files

Collections